Global Saxagliptin Market Report and Forecast 2024-2032

Global Saxagliptin Market Outlook

The global saxagliptin market is expected to grow at a CAGR of 4% in the forecast period of 2024-2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The Asia Pacific Region to Witness a Robust Growth in the Saxagliptin Industry, Owing to Rising Government Funding

The market for saxagliptin is being driven by the rising cases of diabetes across the globe. North America and Europe are the significant markets for saxagliptin globally. This is attributed to a large number of ageing population and the rising prevalence of type II diabetes. The Asia Pacific region is expected to witness a robust growth rate in the forecast period. Countries, especially China and India, are predicted to exhibit a high growth rate of the saxagliptin industry in the Asia Pacific region. Factors such as increasing healthcare expenditure, a large pool of patients, and rising government funding are contributing to the market growth of saxagliptin in the Asia Pacific.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Saxagliptin: Market Segmentation

Saxagliptin is the medicine used to treat diabetes. It works by boosting the level of insulin in the body produced after the meal. The product is marketed under the brand name called Onglyza. Saxagliptin acts on a natural hormone in the body, which is called incretins. The product has various side effects such as urinary tract infection, headache, upper respiratory tract infection, and nasopharyngitis. Saxagliptin can also cause complications like stroke and heart attack.

On the basis of dosage, the market is divided into:

• 2.5 mg
• 5 mg
• Others

Based on distribution channel, the industry can be segmented into:

• Hospital Pharmacy
• Retail Pharmacy
• Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Incidences of Type II Diabetes to Aid the Global Market Growth of Saxagliptin

The market for saxagliptin is being driven by the rising incidences of type II diabetes across the globe. The market drivers, such as increased sedentary lifestyle, rising prevalence of obesity, increased government funding, and junk food habits, are contributing to the market growth of saxagliptin. Further, the rising healthcare awareness is expected to fuel the market growth over the forecast period. The market is expanding due to further innovations taking place in the saxagliptin industry. This is further expected to aid the market growth over the forecast period. However, the market is expected to witness a setback owing to the factors, such as stringent regulations for the approval of drugs and the availability of substitutes for the treatment of diabetes.

Key Industry Players in the Global Saxagliptin Market

The report gives a detailed analysis of the following key players in the global saxagliptin market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• AstraZeneca plc.
• Wellona Pharma
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report